目的：评价支气管动脉灌注化疗药物联合干扰素治疗肺癌的价值。方法：将40例肺癌随机分为2组：支气管动脉灌注化疗药物联合干扰素治疗20例为观察组；单纯支气管动脉灌注化疗药物20例为对照组。对2组病例的近期疗效和生存率分别进行Χ检验。结果：首次治疗肺癌的总有效率（CR+PR）观察组为60.0%（12/20），与对照组40.0%（8/20）比较，差异无显著性（Χ2=1.60，P＞0.05）；但1,2年的生存率观察组分别为 85.0%（17/20）,45.0%（9/20），分别与对照组500%（10/20）,10.0%（2/20）比较，有显著性差异（Χ2值分别为5.58,6.14；P<0.05）。结论：支气管动脉灌注化疗药物联合干扰素治疗能提高肺癌患者的生存率，是一种有价值的治疗方法。

Objective：To evaluate the value of lung cancer treatment by chemotherapeutic drugs through bronchoartery perfusion combined with interferon.Methods：40 cases with lung cancer were randomly divided into 2 groups. 20 cases accepted chemotherapeutic drugs through bronchoartery perfusion combined with interferon were considered as observed group, and the other 20 cases accepted only chemotherapeutic drugs through bronchoartery perfusion as control group. Χ2 test was used to compare the differences of the recent curative effects and survival rates between the two groups. Results：The total effective rate (CR+PR) of the observed group during the first treatment was 60.0% (12/20), which was not significant as compared with that of control group (40.0%) (Χ2= 1.60, P＞0.05). But the survival rates of the observed group during 1 and 2 years were 85.0% (17/20) and 45.0% (9/20), respectively. There were significant differences as compared with 50.0% (10/20) and 10.0% (2/20) in control group (Χ2= 5.58 and 6.14, P＜0.05).Conclusion：Bronchoartery perfusion with chemotherapeutic drugs combined with interferon can raise the survival rates of patients with lung cancer, and is a valuably therapeutic method.